Results 131 to 140 of about 2,808,349 (298)
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
Viruses, 2014 Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance ...
Thibault Mesplède, Mark A. Wainberg
doaj +1 more source
Viral Hybrid Vectors for Somatic Integration - Are They the Better Solution? [PDF]
, 2009 The turbulent history of clinical trials in viral gene therapy has taught us important lessons about vector design and safety issues. Much effort was spent on analyzing genotoxicity after somatic integration of therapeutic DNA into the host genome. Based
Ehrhardt, Anja +2 more
core +4 more sources
HIV Medicine, EarlyView.Abstract Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy.
Kyle Ring +4 more
wiley +1 more source
PLoS ONE, 2017 T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor (INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the prevalence of T97A (pre-existing and emergent) and its impact on INSTI ...
M. Abram +6 more
semanticscholar +1 more source
Characterization of HIV-1 Integrase Reactions with Viral DNA [PDF]
, 2013 HIV-1 integrase (integrase) catalyzes the insertion of viral DNA into human chromosomes and is a focus for development of anti-integrase inhibitors to combat HIV infection. Integrase catalyzes two steps, a DNA-end cleavage reaction (3’-processing), and a
Kettlewell, Joanna
core +1 more source
Resistance to novel drug classes [PDF]
, 2009 Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS: Integrase inhibitors and CCR5
Calvez, V. +3 more
core +1 more source
HIV Medicine, EarlyView.Abstract Introduction Women remain underrepresented in studies on immunological response (IR) among virally suppressed people living with HIV. Despite receiving antiretroviral therapy (ART) some individuals do not attain an IR, increasing their risk of non‐AIDS morbidity and mortality.
Josefin Nilsson +6 more
wiley +1 more source
Infection and Drug Resistance, 2021 Xiaorong Peng,* Yufan Xu,* Ying Huang, Biao Zhu State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China*These ...
Peng X, Xu Y, Huang Y, Zhu B
doaj
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
Retrovirology, 2015 BackgroundDolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1–infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical reports of dolutegravir for HIV-2 ...
Robert A. Smith +6 more
semanticscholar +1 more source
Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. [PDF]
, 2017 Objective The contribution of hepatitis C virus (HCV) infection to the risk of heart failure in human immunodeficiency virus (HIV)-coinfected persons is unknown.
Ambale-Venkatesh, Bharath +9 more
core +2 more sources